Heatwurx (NASDAQ:PCSA) Announces Earnings Results

by · The Cerbat Gem

Heatwurx (NASDAQ:PCSA – Get Free Report) issued its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01, FiscalAI reports.

Heatwurx Stock Down 3.2%

NASDAQ PCSA traded down $0.01 on Friday, hitting $0.31. The stock had a trading volume of 2,096,921 shares, compared to its average volume of 9,369,590. The company’s 50-day moving average is $0.27 and its two-hundred day moving average is $0.25. Heatwurx has a one year low of $0.15 and a one year high of $1.50. The stock has a market cap of $15.40 million, a price-to-earnings ratio of -0.13 and a beta of 1.45.

Analysts Set New Price Targets

PCSA has been the topic of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Heatwurx in a research note on Wednesday, October 8th. Zacks Research downgraded shares of Heatwurx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. Finally, HC Wainwright decreased their price target on shares of Heatwurx from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, September 2nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $1.00.

Read Our Latest Stock Analysis on Heatwurx

Heatwurx Company Profile

(Get Free Report)

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.

See Also